Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin.

Research, 8(2) 2024 [138-146]

International Journal of Pharmacology and

Clinical Research (IJPCR)
IJPCR |Vol.8 | Issue 2 | Apr - Jun -2024
[Link]
ISSN: 2349-5448 DOI : [Link]

Review

Advances in Understanding and Treating Schizophrenia:

A Comprehensive Review
Amna Hameed Thayyil*1, Zeenath P1, Aiswarya Lakshmi P1, E Tamil Jothi 1, G Babu2,
Anson S Maroky1
1
Department of Pharmacology, Devaki Amma Memorial College of Pharmacy, Malappuram
[Link]-673634
2
Department of Pharmaceutical Chemistry, Devaki Amma Memorial College of Pharmacy,
Malappuram [Link]-673634

*Author for Correspondence: Amna Hameed Thayyil

Email: amnahameedthayyil@[Link]

Abstract
Schizophrenia is a debilitating psychiatric disorder characterized by
Published on: 30 Mar2024 psychotic symptoms, including hallucinations and delusions, which profoundly impact
emotions, behavior, and cognition. Its global prevalence underscores its significance
as a public health concern, with substantial social and economic burdens. The
Published by: pathophysiology of schizophrenia implicates dysregulation of neurotransmitters,
DrSriram Publications particularly dopamine, serotonin, and glutamate. Schizophrenia is a complex
psychiatric disorder characterized by a wide range of symptoms and cognitive
impairments, profoundly impacting affected individuals and society. This article
provides an overview of schizophrenia, including its epidemiology, symptoms, and
2024| All rights reserved. underlying pathophysiology involving dopamine, serotonin, and glutamate. It
discusses the current treatment landscape, emphasizing the importance of both
pharmacological and non-pharmacological interventions. Non-pharmacological
approaches such as cognitive remediation, physical exercise, non-invasive brain
stimulation, complementary interventions, cognitive behavioral therapy, and yoga
Creative Commons therapy are explored, highlighting their efficacy in improving functional outcomes.
Attribution 4.0 Additionally, the article reviews pharmacological strategies targeting dopamine,
International License. serotonin, and glutamate receptors, as well as emerging treatments involving
adrenergic, cholinergic, muscarinic, and other agents. Despite advancements,
challenges in implementing evidence-based interventions persist, underscoring the
need for further research and collaboration to enhance schizophrenia management and
improve the lives of affected individuals.

Keywords: Schizophrenia, Psychosis, Treatment strategies, Pharmacological

interventions, Nonpharmacological interventions.

138
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

INTRODUCTION
Schizophrenia is a psychological condition characterized by psychotic symptoms, including
hallucinations and delusions, which profoundly impact emotions, behavior, and cognitive processes. Psychosis, a
hallmark of schizophrenia, entails a loss of connection with reality. Often referred to as a "split mind,"
schizophrenia manifests as a mental disorder marked by disturbances in perception or expression of reality,
coupled with significant social or occupational impairments. Individuals with schizophrenia may experience
delusions, hallucinations, disorganized speech, grossly disorganized behavior, or catatonic states. This disorder
affects approximately 1% of the global population, transcending geographical boundaries from China and Finland
to the United States and New Guinea. Schizophrenia ranks among the top five causes of disability in developed
nations, alongside conditions like heart disease, arthritis, substance abuse, and HIV. In the United States, a
significant portion of those with schizophrenia face homelessness, hospitalization, or incarceration, collectively
representing about 16% of the affected population, while 34% live independently. According to the World Health
Organization (WHO), over 40 million people worldwide grapple with mental disorders such as schizophrenia and
dementia. Tragically, over 10% of individuals diagnosed with schizophrenia ultimately die by suicide,
underscoring its severity as a global psychiatric illness[1].
The symptoms of schizophrenia are categorized into three main groups: positive symptoms, negative
symptoms, and cognitive symptoms. Positive symptoms involve alterations from typical functioning and
encompass experiences like delusions, hallucinations, paranoia, and agitation. Negative symptoms entail
deficiencies in functioning and encompass behaviors such as social withdrawal, reduced emotional expression,
and lack of motivation. Cognitive symptoms involve impairments in cognitive abilities like learning, memory,
attention, and executive functions[2].
The pathophysiology of schizophrenia follows three hypothesizes mainly, Dopamine, Serotonin and
Glutamate.
Dopamine: Dysregulated dopamine signaling is central to schizophrenia, a complex psychiatric disorder marked
by disturbances in cognition, perception, and behavior. Excessive dopamine activity in the mesolimbic pathway
is linked to positive symptoms like hallucinations and delusions, while reduced dopamine function in the
mesocortical pathway contributes to negative symptoms such as social withdrawal and cognitive deficits.
Antipsychotic medications primarily target dopamine receptors to alleviate symptoms, highlighting the crucial
role of dopamine modulation in managing schizophrenia.
Glutamate: Glutamate, the primary excitatory neurotransmitter in the brain, is implicated in the
pathophysiology of schizophrenia. Dysregulation of glutamate signaling, particularly involving the N-methyl-D-
aspartate (NMDA) receptor, contributes to cognitive, affective, and psychotic symptoms characteristic of the
disorder. Neuroimaging studies have revealed alterations in glutamate levels and receptor densities in brain
regions associated with schizophrenia. Preclinical research using animal models has demonstrated that
manipulating glutamatergic neurotransmission can induce schizophrenia-like symptoms. Understanding the role
of glutamate in schizophrenia may lead to the development of novel therapeutic interventions targeting glutamate
neurotransmission to improve treatment outcomes.
Serotonin: While the exact role of serotonin in schizophrenia is not fully understood, research suggests
that disturbances in serotonin neurotransmission, particularly involving serotonin receptors, may contribute to
certain symptoms of the disorder. Medications targeting serotonin receptors, such as atypical antipsychotics, are
commonly used in schizophrenia treatment, indicating a potential therapeutic relevance of serotonin modulation.
The majority of treatment approaches are founded on these theoretical frameworks.

NON PHARMACOLOGICAL APPROACHES

COGNITIVE REMEDIATION
Cognitive Remediation (CR) is a behavioral intervention tailored to address Cognitive Impairment
Associated with Schizophrenia (CIAS), aiming to enhance psychosocial functioning and real-world outcomes
over the long term[3-6]. Recent systematic reviews and meta-analyses have demonstrated the efficacy of CR in
improving CIAS, with notable gains in functional abilities[7-9]. Factors such as the involvement of a trained
therapist, the development of new cognitive strategies, techniques to transfer improvements into daily life,
integration with psychiatric rehabilitation programs, and combination with other evidence-based interventions
consistently enhance CR outcomes[10]. Interestingly, individual characteristics, including age, do not significantly
affect CR effectiveness, suggesting its feasibility across different age groups, including older patients.
This robust evidence has led to CR receiving the highest recommendation level in European Psychiatric
Association guidelines for CIAS treatment. Additionally, recent studies have highlighted CR's favorable
acceptability profile, aligning with other psychosocial interventions commonly used in schizophrenia
rehabilitation[11]. Factors influencing CR engagement include the severity of CIAS and negative symptoms,
intrinsic motivation levels, and baseline self-efficacy. Furthermore, research indicates that CR benefits both

139
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

pharmacological treatment responders and individuals with treatment-resistant schizophrenia, underscoring its
effectiveness across various clinical presentations[12]. Moreover, participants with greater clinical severity, older
age, and lower education levels tend to experience more significant functional improvements post-CR. Despite
these endorsements and evidence, the implementation of CR and other evidence-based non-pharmacological
treatments in schizophrenia management still faces challenges[13].

PHYSICAL EXERCISE
Indeed, the efficacy of physical exercise interventions in treating CIAS has been extensively documented
in numerous large-scale meta-analyses. While the European Psychiatric Association guidelines recommend their
use, the level of recommendation is lower compared to CR due to a lack of systematic assessments regarding
intervention types and their effects on functional outcomes in routine rehabilitation practice[14-16]. However, recent
meta-analyses have shed light on potential moderators of physical exercise interventions' effects on CIAS. Aerobic
exercise, conducted in group settings under the supervision of trained professionals, has been identified as the
most effective form[17]. Additionally, cognitive improvements exhibit a dose-response relationship, with
significant benefits observed with a minimum duration of ≥ 90 minutes per week for ≥ 12 weeks, indicating a
direct correlation between physical exercise and cognitive enhancements[18]. Moreover, another meta-analysis
focusing on functional outcomes in people with SSD revealed moderate to large effects, particularly in aerobic
exercise interventions of moderate to vigorous intensity.
With these findings, physical exercise-based interventions can now be recognized as evidence-based
treatments for CIAS[19,20]. Recent studies have also demonstrated the feasibility of combining physical exercise
programs with CR, yielding greater benefits than either intervention alone and leading to faster cognitive
performance improvements[21].
However, similar to CR and other psychosocial interventions for SSD, the implementation of physical
exercise interventions faces challenges in clinical services. Currently, they are inconsistently provided to service
users, even within inpatient settings. Addressing this issue requires further research to understand implementation
facilitators and barriers while simultaneously advocating for policy and organizational changes to bridge the gap
between research findings and clinical practice[22,23].

NON-INVASIVE BRAIN STIMULATION

In addition to psychosocial interventions, another category of non-pharmacological treatments for people
with SSD involves brain stimulation techniques, particularly non-invasive methods[24]. These techniques, mainly
transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS), have been explored
for treating CIAS. TDCS involves applying low-amplitude direct currents through scalp electrodes, modulating
cortical excitability in a non-focal manner by altering neuronal membrane potentials. On the other hand, TMS
delivers electromagnetic pulses through a coil to stimulate specific brain areas, inducing secondary electric
currents and modulating neuronal firing rates[25-28].
Recent meta-analyses have indicated that both tDCS and TMS could have positive effects in treating
CIAS[29]. Specifically, they have shown small improvements, particularly in the domain of working memory, with
tDCS having more consistent evidence supporting its effectiveness.
However, there is considerable variability in the stimulation protocols used in tDCS trials, including
differences in electrode placement, session length, timing, and overall treatment duration. This methodological
diversity may obscure the true potential of the treatment, and it's possible that certain protocols could yield
consistent benefits in CIAS and other key aspects of SSD [30]. Further research is needed to identify optimal
treatment modalities and durations to accurately assess the effectiveness of non-invasive brain stimulation,
essential for providing clear recommendations in clinical practice.
Furthermore, a recent systematic review and meta-analysis compared the effectiveness of combining
non-invasive brain stimulation with CR versus CR alone on cognitive and functional outcomes. While the
combined approach showed superior benefits in the working memory domain, especially in SSD, the majority of
included studies exhibited a significant risk of bias. This underscores the necessity for more research on the
effectiveness of this combination, particularly in SSD populations[31,32].

COMPLEMENTARY INTERVENTION AND DIET

Brown et al[33]. found that individuals with schizophrenia had diets higher in total fat and lower in fiber
compared to a control group matched for age, gender, and education[34]. However, the intake of unsaturated fat
was similar between both groups. Another study investigated the dietary habits of individuals with schizophrenia
residing in assisted-living facilities in Scotland, alongside a control group matched for sex, age, smoking, and
employment status[35]. The majority of schizophrenia patients were overweight or obese, and their saturated fat
intake exceeded recommended levels.
Furthermore, individuals with schizophrenia were found to consume less total fiber, retinol, carotene,
vitamin C, vitamin E, fruits, and vegetables compared to the control group. McCreadie et al. examined the dietary

140
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

patterns of schizophrenia patients, with a particular focus on fruit and vegetable consumption and smoking
behavior[36]. The findings indicated poor dietary choices, especially among male patients.
Graham et al. proposed that administering vitamin D to individuals with schizophrenia could alleviate
negative symptoms. Similarly, Strassnig et al. investigated the dietary habits of community-dwelling adults with
schizophrenia, revealing higher consumption of protein, carbohydrates, and fats compared to a control group [37].
Such dietary habits may increase the risk of cardiovascular diseases, type II diabetes, and systemic inflammation,
contributing to the shortened lifespan observed in individuals with schizophrenia.
Joseph et al. suggested that high-fiber diets could enhance the immune and cardiovascular systems,
potentially preventing premature mortality in schizophrenia[38]. Summarizing the beneficial effects of
complementary interventions, including folic acid supplements, vitamin C, E, and B, in managing schizophrenia
symptoms[39]. Although vitamin D administration may improve daily functioning, further research is necessary to
explore the relationship between complementary medications and schizophrenia comprehensively[40,41].

COGNITIVE BEHAVIOR THERAPY

Cognitive behavioral therapy (CBT) is a therapeutic method aimed at altering undesirable patterns of
thinking, feeling, and behavior. It encompasses practical strategies for self-help that have been proven to alleviate
positive symptoms in schizophrenia by integrating cognitive and behavioral therapy techniques. Morrison
provides an overview of CBT's application in addressing primary symptoms and social deficits in individuals with
schizophrenia. Additionally, CBT is suggested as a complement to antipsychotic medications, potentially
enhancing treatment outcomes[41].
Within CBT, various techniques are employed to effectively modify thoughts and behaviors in
schizophrenia. For instance, cognitive restructuring involves challenging the evidence behind delusional beliefs,
guiding patients to recognize and challenge negative thoughts, and replacing them with more realistic and positive
ones[42]. CBT has also demonstrated effectiveness in addressing homelessness and enhancing social relationships
through cognitive enhancement.
Over the past 15 years, validation studies have established CBT as one of the most commonly utilized
therapies for schizophrenia in the UK, often used alongside medications. Both the UK National Health Service
(NHS) and the American Psychiatric Association recommend CBT as a primary treatment for schizophrenia,
especially for individuals with persistent psychotic symptoms[43]. CBT has shown promise in reducing
disorganized behavior and improving various symptoms, including positive and negative symptoms, mood, and
social anxiety.
Involving family members in CBT sessions can foster a collaborative treatment environment and
promote active engagement in therapy. Assigning homework tasks in CBT can help alleviate distressing
symptoms, encourage medication adherence, facilitate community integration, and promote healthy lifestyle
choices. Combining CBT with antipsychotic medication has been found to enhance efficacy compared to
medication alone.
Studies have demonstrated significant reductions in positive and negative symptoms and depression with
CBT over a nine-month period, with sustained improvement observed in follow-up assessments [44]. To effectively
implement CBT for schizophrenia, a thorough understanding of the patient's symptoms is crucial, followed by
addressing issues related to positive and negative symptoms.
Furthermore, CBT has been shown to decrease suicidal thoughts and violent behavior, promote regular
exercise, facilitate community integration, prevent stigmatization, and discourage substance abuse in individuals
with schizophrenia[45]. A summary of the holistic management of schizophrenia and associated CBT intervention
options is provided.

YOGA THERAPY
Yoga therapy is another approach for managing symptoms of schizophrenia, often used in conjunction
with pharmacological medications. Solely relying on medication may not achieve all desired effects in symptom
management, particularly for negative symptoms. Integrating yoga alongside antipsychotic medications has
shown promise in addressing both positive and negative symptoms more effectively than medications alone [47].
Moreover, pharmacological treatments can often lead to weight gain in individuals with schizophrenia, whereas
yoga therapy has been found to help mitigate this side effect.
In a study by Gangadhar et al., two groups of patients receiving antipsychotic medications were
compared, with one group receiving yoga therapy and the other group undergoing a set of physical exercises[46].
After a month of training (comprising at least 12 sessions), the yoga group exhibited better scores for negative
symptoms and social dysfunction compared to the other group. Similarly, Vancampfort et al. observed that
practicing yoga reduces psychiatric symptoms, improves mental and physical quality of life, and lowers metabolic
risk.
The effectiveness of yoga therapy is likely attributed to the release of oxytocin in the body, a hormone
associated with well-being. In a study where oxytocin was administered alongside antipsychotic medications to

141
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

40 patients, improvements were observed in both negative and positive symptoms. The benefits of yoga therapy
are multifaceted, including reductions in psychotic symptoms and depression, improvements in cognition, and
enhancements in overall quality of life[48].

PHARMACOLOGICAL APPROACHES
Antipsychotic drugs are classified into various categories based on their chemical structure and pharmacological
properties. These medications are an essential component of the pharmacological approach to treating
schizophrenia, aimed at alleviating symptoms and improving the overall quality of life for individuals affected by
this disorder.

Fig 1: Tripathi Book of Essential Pharmacology

DRUGS AFFECTING DOPAMINERGIC HYPOTHESIS

Scientists have studied drugs that affect dopamine receptors extensively, hoping to find better treatments
for schizophrenia. These drugs work by interacting with different types of dopamine receptors in the brain. For
instance, dopamine D1 receptors are involved in cognitive functions like working memory. Some medications
that activate these receptors have shown potential for improving cognitive function in schizophrenia patients.
However, one such drug, dihydrexidine, didn't lead to significant improvements in symptoms in a study, even
though it increased brain activity. Other medications, like talipexole and preclamol, partially activate dopamine
D2 receptors. While they haven't been very effective in treating the main symptoms of schizophrenia, they may
help with negative symptoms such as lack of motivation.
One promising new medication, cariprazine, works by partially activating dopamine receptors and also
affecting serotonin receptors. Early studies suggest it may have fewer side effects than other medications.
Scientists are also exploring medications that target dopamine D3 and D4 receptors. However, it's still unclear
how effective these drugs will be in treating schizophrenia. Overall, while medications that target dopamine
receptors show promise, more research is needed to find the best treatments for schizophrenia [49, 51].

DRUGS AFFECTING SEROTONIN HYPOTHESIS

Certain medications target serotonin receptors, which are involved in regulating mood and cognitive
function, in addition to dopamine receptors. For example, drugs that activate the 5-HT1A receptor, such as
tandospirone and buspirone, have been found to enhance certain aspects of cognition in schizophrenia patients
when combined with other antipsychotic medications. Similarly, medications that block the 5-HT2A receptor,
like ritanserin, may help reduce negative symptoms and depressed mood in schizophrenia patients. However,
some newer drugs targeting this receptor, such as M-100907 and SR-46349B, haven't shown consistent
effectiveness in clinical trials.
Another approach involves using drugs that act as inverse agonists at the 5-HT2A receptor, such as
pimavanserin. These drugs may help improve symptoms and reduce side effects like akathisia. Additionally,
medications targeting serotonin receptors like 5-HT2C, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 are being investigated
for their potential to treat schizophrenia symptoms and improve cognitive function. These drugs may offer new
options for patients who don't respond well to traditional antipsychotic medications[52,53].
Overall, while targeting serotonin receptors shows promise, more research is needed to fully understand their role
in schizophrenia and develop effective treatments.

142
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

DRUGS AFFECTING GLUTAMINERGIC HYPOTHESIS

Glycine site allosteric modulators are substances that affect the NMDA receptors, which are implicated
in schizophrenia. These modulators, like glycine, D-cycloserine, D-serine, and D-alanine, are studied for their
potential to improve symptoms of schizophrenia by enhancing NMDA receptor activity. A recent analysis found
that glycine therapy reduced overall psychopathology, positive symptoms, and depressive symptoms in
schizophrenia patients. However, while D-serine showed effectiveness in reducing total psychopathology,
negative symptoms, and cognitive symptoms, D-cycloserine did not have significant effects. Furthermore, glycine
site modulators added to second-generation antipsychotics (SGAs) were more effective than first-generation
antipsychotics or clozapine in improving negative symptoms and overall psychopathology. However, these
modulators did not consistently improve cognitive function in schizophrenia.
Another approach involves glycine transporter inhibitors, which increase NMDA receptor activity by
blocking the reuptake of glycine. Sarcosine, a glycine transporter inhibitor, showed efficacy in improving positive
and negative symptoms when added to existing antipsychotic medications. However, it did not show effectiveness
when added to clozapine.
A recent study found that RG1678, a GlyT1 inhibitor, improved negative symptoms in schizophrenia
patients, but another GlyT1 inhibitor, Org-25935, did not show significant improvement in a different study. More
research is needed to determine the effectiveness of GlyT1 inhibitors in treating cognitive deficits in
schizophrenia.
Metabotropic glutamate receptor agonists, which target different subtypes of glutamate receptors, have
shown promise in preclinical studies but have yielded mixed results in clinical trials. Similarly, metabotropic
glutamate receptor modulators, which enhance glutamate transmission, have shown potential benefits in
preclinical studies but require further investigation in clinical populations. Ampakines, which enhance AMPA
receptor function, have not shown significant effects on symptoms or cognitive impairment in schizophrenia
patients in clinical trials. Glutathione precursors, like N-acetylcysteine (NAC), have shown promise in improving
symptoms, particularly negative symptoms, and cognitive function in schizophrenia patients, but more research
is needed to confirm their efficacy[54,55]. In summary, while several glutamatergic modulators show promise as
adjunctive treatments for schizophrenia, further research is needed to determine their effectiveness and optimal
use.

ADRENERGIC AGENTS
Adrenergic agents: The role of a2 adrenergic receptors (ARs) in cognitive function, particularly in
working memory, has been explored. Agonists like clonidine and guanfacine show promise in improving
cognition in preclinical and early clinical trials. Antagonists like clozapine and risperidone, on the other hand,
may contribute to the 'atypicality' of second-generation antipsychotics (SGAs) by enhancing dopaminergic
transmission. Further large-scale trials are needed to determine the potential benefits of a2 AR agonists in
schizophrenia. It's uncertain whether agonists or antagonists of a2 ARs will have greater benefits.

COMT INHIBITORS
COMT inhibitors: Catechol-O-methyl transferase (COMT) inhibitors, like tolcapone, show potential in
enhancing prefrontal cognitive function in preclinical and early human studies. However, due to safety concerns
and restricted use, further investigation is required, especially with COMT inhibitors like tolcapone and
entacapone in phase II trials.

CHOLINERGIC AGENTS
Cholinergic agents: Nicotinic acetylcholine receptors (nAChRs) have implications in cognitive function,
particularly the a7 subtype. Various agonists are under investigation for adjunctive treatment in schizophrenia,
with mixed results in clinical trials. Additionally, a4-b2 nAChRs are targeted for cognitive enhancement, but
results have been inconsistent, especially with agents like varenicline, which also poses psychiatric side effects.

MUSCARINIC AGENTS
Muscarinic agents: Partial agonists of muscarinic receptors, like xanomeline, show efficacy in improving
cognition and general psychopathology in schizophrenia. However, further studies are needed to confirm their
effectiveness.

OTHER AGENTS
Other agents: Various compounds like cannabinoid-1 receptor antagonists, GABA-A-positive
modulators, anti-inflammatory agents, neurokinin-3 receptor antagonists, estrogen, neurosteroids, omega-3 fatty
acids, oxytocin, PDE10A inhibitors, secretin, erythropoietin, and ginkgo are being investigated for their potential
in schizophrenia treatment, targeting different pathways including neurotransmitter modulation, anti-

143
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

inflammatory effects, neuroprotection, and cognitive enhancement. Results from clinical trials are mixed, with
some showing promise but requiring further validation through larger and longer studies [56].

CONCLUSION
Schizophrenia remains a challenging mental disorder that profoundly affects the people it targets and
society as a whole. It is a complex phenomenon with its varied symptoms, cognitive impairment among others
thus both therapy methods such as pharmacological and non-pharmacological ones should be employed. Some of
these approaches include physical exercise, yoga therapy, cognitive remediation (CR), complementary
interventions, non-invasive brain stimulation (NIBS) and cognitive behavioral therapy (CBT). However despite
the various benefits attendant to their use, there exist challenges associated with implementation of these therapies
necessitating further research and advocacy in order to bridge the gap between evidence-based practices and
clinical services. Antipsychotic drugs are still very much used in treating schizophrenia but an ongoing search for
new drug targets has led to an exploration of novel approaches based on dopamine, serotonin and glutamate
hypotheses. Though several drugs have shown promise in animal studies or early human trials, more work needs
to be done before one can say they are effective and safe enough for general clinical use.

REFERENCES
1. Ahmed MdN, Kabidul Azam MdN. Traditional Knowledge and Formulations of Medicinal Plants Used
by the Traditional Medical Practitioners of Bangladesh to Treat Schizophrenia Like Psychosis.
Schizophrenia Research and Treatment. 2014;2014:1–10.
2. El-Sayed El-Sisi A, Sokkar SS, El-Sayed El-Sayad M, Sayed Ramadan E, Osman EY. Celecoxib and
omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry
in amphetamine-induced model of schizophrenia. Biomedicine & Pharmacotherapy. 2016 Aug;82:425–31.
3. Bowie CR, Bell MD, Fiszdon JM, et al. Cognitive remediation for schizophrenia: An expert working group
white paper on core techniques. Schizophrenia Res2020;215:49-53. [Link]
schres.2019.10.047
4. Wykes T, Huddy V, Cellard C, et al. A Meta-Analysis of Cognitive Remediation for Schizophrenia:
Methodology and Effect Sizes. Am J Psychiatry 2011;168:472-85. [Link]
[Link].2010.10060855
5. Kambeitz-Ilankovic L, Betz LT, Dominke C, et al. Multi-outcome meta-analysis (MOMA) of cognitive
remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay
between multiple outcomes. Neuroscience Biobehav Rev 2019;107:828-45. https://
[Link]/10.1016/[Link].2019.09.031
6. Lejeune JA, Northrop A, Kurtz MM. A Meta-analysis of Cognitive Remediation for Schizophrenia:
Efficacy and the Role of Participant and Treatment Factors. Schizophr Bull 2021;47:997-1006. [Link]
org/10.1093/schbul/sbab022
7. Vita A, Barlati S, Ceraso A, et al. Effectiveness, Core Elements, and Moderators of Response of Cognitive
Remediation for Schizophrenia: a systematic review and meta-analysis of randomized clinical trials.
JAMA Psychiatry 2021;78:848-58. https:// [Link]/10.1001/jamapsychiatry.2021.0620
8. Yeo H, Yoon S, Lee J, et al. A metaanalysis of the effects of social-cognitive training in schizophrenia:
The role of treatment characteristics and study quality. Br J Clin Psychol 2022;61:37-57.
[Link] .
9. Seccomandi B, Agbedjro D, Bell M, et al. Exploring the role of age as a moderator of cognitive remediation
for people with schizophrenia. Schizophr Res 2021;228:29-35. [Link]
schres.2020.11.060.
10. Vita A, Barlati S, Ceraso A, et al. Acceptability of cognitive remediation for schizophrenia: a systematic
review and metaanalysis of randomized controlled trials. Psychol Med 2023;53:3661-71. [Link]
org/10.1017/S0033291722000319
11. Altman RAE, Tan EJ, Rossell SL. Factors Impacting Access and Engagement of Cognitive Remediation
Therapy for People with Schizophrenia: A Systematic Review. Can J Psychiatry 2023;68:139-51. https://
[Link]/10.1177/07067437221129073
12. Martini F, Spangaro M, Bechi M, et al. Improving outcome of treatment-resistant schizophrenia: effects of
cognitive remediation therapy. Eur Arch Psychiatry Clin Neurosci 2023 Dec 19. [Link]
org/10.1007/s00406-023-01731-6
13. Sampedro A, Peña J, Sánchez P, et al. Moderators of functional improvement after integrative cognitive
remediation in schizophrenia: toward a personalized treatment approach. Psychiatry Res 2023;329:115495.
[Link] psychres.2023.115495

144
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

14. Schmitt A, Maurus I, Rossner MJ, et al. Effects of Aerobic Exercise on Metabolic Syndrome,
Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. Front Psychiatry
2018;9:690. [Link]
15. Fernández-Abascal B, Suárez-Pinilla P, Cobo-Corrales C, et al. In- and outpatient lifestyle interventions
on diet and exercise and their effect on physical and psychological health: a systematic review and meta-
analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode
of psychosis. Neurosci Biobehav Rev 2021;125:535-68. [Link] neubiorev.2021.01.005
16. Firth J, Cotter J, Elliott R, et al. A systematic review and meta-analysis of exercise interventions in
schizophrenia patients. Psychol Med 2015;45:1343-61. [Link] .
17. Sabe M, Kaiser S, Sentissi O. Physical exercise for negative symptoms of schizophrenia: Systematic
review of randomized controlled trials and meta-analysis. Gen Hosp Psychiatry 2020;62:13-20.
[Link]
18. Dauwan M, Begemann MJH, Heringa SM, et al. Exercise Improves Clinical Symptoms, Quality of Life,
Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr
Bull 2016;42:588-99. [Link]
19. Firth J, Stubbs B, Rosenbaum S, et al. Aerobic Exercise Improves Cognitive Functioning in People With
Schizophrenia: A Systematic Review and Meta-Analysis. Schizophr Bull 2017;43:546-56.
[Link]
20. Shimada T, Ito S, Makabe A, et al. Aerobic exercise and cognitive functioning in schizophrenia: An
updated systematic review and meta-analysis. Psychiatry Res 2022;314:114656.
[Link]
21. Korman N, Stanton R, Vecchio A, et al. The effect of exercise on global, social, daily living and
occupational functioning in people living with schizophrenia: a systematic review and meta-analysis.
Schizophr Res 2023;256:98-111. [Link]
22. Dai Y, Ding H, Lu X, et al. CCRT and aerobic exercise: a randomised controlled study of processing speed,
cognitive flexibility, and serum BDNF expression in schizophrenia. Schizophrenia (Heidelb) 2022;8:84.
[Link]
23. Deste G, Corbo D, Nibbio G, et al. Impact of Physical Exercise Alone or in Combination with Cognitive
Remediation on Cognitive Functions in People with Schizophrenia: A Qualitative Critical Review. Brain
Sci 2023;13:320.
24. Lefaucheur JP, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of
repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125:2150-206.
[Link]
25. Begemann MJ, Brand BA, Ćurčić-Blake B, et al. Efficacy of non-invasive brain stimulation on cognitive
functioning in brain disorders: a meta-analysis. Psychol Med 2020;50:2465-86.
[Link]
26. Sloan NP, Byrne LK, Enticott PG, Lum JAG. Non-Invasive Brain Stimulation Does Not Improve Working
Memory in Schizophrenia: A Meta-Analysis of Randomised Controlled Trials. Neuropsychol Rev
2021;31:115-38. [Link]
27. Jiang Y, Guo Z, Xing G, et al. Effects of High-Frequency Transcranial Magnetic Stimulation for Cognitive
Deficit in Schizophrenia: a meta-analysis. Front Psychiatry [Link].
[Link]
28. Liu Y, Gu N, Cao X, et al. Effects of transcranial electrical stimulation on working memory in patients
with schizophrenia: a systematic review and meta-analysis. Psychiatry Res 2021;296:113656.
[Link]
29. Narita Z, Stickley A, DeVylder J, et al. Effect of multi-session prefrontal transcranial direct current
stimulation on cognition in schizophrenia: a systematic review and meta-analysis. Schizophr Res
2020;216:367-73. [Link]
30. Sun CH, Jiang WL, Cai DB, et al. Adjunctive multi-session transcranial direct current stimulation for
neurocognitive dysfunction in schizophrenia: A meta-analysis. Asian J Psychiatr 2021;66:102887.
[Link]
31. Lisoni J, Baldacci G, Nibbio G, et al. Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct
Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with
schizophrenia: Results of a randomized double-blind sham-controlled trial. J Psychiatr Res 2022;155:430-
42. [Link]
32. Poppe A, Ritter FD, Bais L, et al. The efficacy of combining cognitive training and noninvasive brain
stimulation: A transdiagnostic systematic review and meta-analysis. Psychol Bull 2023 Nov13
[Link]
33. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol
Med. (1999) 29:697–701. [Link]

145
 Amna Hameed Thayyil et al / Int. J. of Pharmacology and Clin. Research, 8(2) 2024 [138-146]

34. McCreadie R, MacDonald E, Blackock C, Tilak-Singh D, Wiles D, Halliday J, et al. Dietary intake of
schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ. (1998) 317:784–785.
[Link]
35. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, et al. Weight gain associated with increased food
intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Am J Psychiatry. (2002) 159:1055–7. [Link]
36. Kalaydjian AE, Eaton W, Cascella N, Fasano A. The gluten connection: the association between
schizophrenia and celiac disease. Acta Psychiatr Scand. (2006) 113:82–90. [Link]
0447.2005.00687.x
37. McCreadie RG. Diet, smoking, and cardiovascular risk in people with schizophrenia: descriptive study. Br
J Psychiatry (2003) 183:534–9. [Link]
38. Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low
vitamin D status with positive, negative and cognitive symptom domains in people with first-episode
schizophrenia. Early Interv Psychiatry (2015) 9:397–405. [Link]
39. Strassnig M, Singh BJ, Ganguli,. R. Dietary intake of patients with schizophrenia. Psychiatry (Edgmont).
(2005) 2:31–5. [Link]
40. Kraft DB, Westman CE. Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and
review of the literature. Nutr Metabol. (2009) 6:10. [Link]
41. Tai S, Turkington D. The evolution of cognitive behavior therapy for schizophrenia: current practice and
recent developments. Schizo Bull. (2009) 35:865–73. [Link]
42. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws RK. Cognitive behavioural therapy for the
symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J
Psychiatry (2014) 204:20–9. [Link]
43. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes clinical
models, and methodological rigor. Schizophr Bull. (2008) 34:523–37.
[Link]
44. Pinto A, La Pia S, Menella R. Cognitive behavioural therapy and clozapine for patients with schizophrenia.
Psychiatr Serv. (1999) 50:901–4 [Link]
45. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry.
(2006) 163:365–73. [Link]
46. Gangadhar N, Varambally S. Yoga therapy for schizophrenia. Int J Yoga. (2012) 5:85–91.
[Link]
47. Vancampfort DL, Probst M, Helvik Skjaerven L., Catalán-Matamoros D, Lundvik-Gyllensten A, Gómez-
Conesa A, et al. Systematic review of the benefits of physical therapy within a multidisciplinary care
approach for people with schizophrenia. Phys Ther. (2012) 92:1–13. [Link]
48. Feifel D. Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother. (2011) 11:157–9.
[Link]
49. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005; 162: 1984-
-1985.
50. Kim DH, Stahl SM. Antipsychotic drug development. Curr Top Behav Neurosci 2010; 4: 123--139.
51. Cutler A, Ball S, Stahl SM. Dosing atypical antipsychotics. CNS Spectr 2008; 13: 1--16.
52. Miyake N, Miyamoto S, Jarskog LF. New serotonin/dopamine antagonists for the treatment of
schizophrenia: are we making real progress? Clin Schizophr Relat Psychoses in press.
53. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R et al. Pharmacological profile of
lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor
activity. J Pharmacol Exp Ther 2010; 334: 171--181.
54. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in
schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010; 16: 522--537.
55. Hashimoto A, Oka T. Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol
1997; 52: 325—353.
56. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of
schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic
agents. Molecular Psychiatry [Internet]. 2012 May 15;17(12):1206–27. Available from:
[Link]

146